Xylo Technologies's EBIT is $-8.5M, below the Healthcare sector average of $23B.
Get informed when a big investor buys or sells
+ FollowAs of Dec 31, 2024
Trailing 12 months ending Dec 31, 2024
Xylo Technologies (XYLO) currently reports a EBIT of $-8.5M as of December 2024. That compares with $-16M in the prior-year period — up 48.2% year over year. That is below the Healthcare sector average of $23B. Use the charts on this page to explore Xylo Technologies's EBIT history and peer comparisons.
Xylo Technologies's EBIT increased from $-16M to $-8.5M — a 48.2% year-over-year increase (period ending December 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Xylo Technologies's EBIT of $-8.5M is lower than the Healthcare sector average of $23B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Xylo Technologies reported $-8.5M in EBIT as of December 2024. That compares with $-16M in the prior-year period — up 48.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current EBIT of $-8.5M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $23B. From there, open related valuation or income-statement pages for Xylo Technologies, and consider following XYLO for alerts when major investors trade the stock.